BIOGEN INC. is 10.9x more valuable than Tarsus Pharmaceuticals, Inc. by market capitalization ($28.68 B vs $2.64 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | TARS | BIIB |
|---|---|---|
| Market cap | $2.64 B | $28.68 B |
| US-listed rank | #1904 | #476 |
| Revenue (latest FY) | $451.36M | $9.89B |
| Net income (latest FY) | -$66.00M | $1.29B |
| Net margin | -14.6% | 13.1% |
| P/E (trailing FY) | - | 22.2 |
| SEC filings | 617 | 2,690 |
BIOGEN INC. is 10.9x more valuable than Tarsus Pharmaceuticals, Inc. by market capitalization ($28.68 B vs $2.64 B).
In their latest fiscal years, Tarsus Pharmaceuticals, Inc. reported $451.36M in revenue while BIOGEN INC. reported $9.89B.
Full pages: Tarsus Pharmaceuticals, Inc. and BIOGEN INC., or browse the full rankings.